Drug Formulary Review Archives – February 1, 2006
February 1, 2006
View Issues
-
Unapproved abbreviations most problematic patient safety goal
Almost half of hospitals trying to be compliant with patient safety goals of the Joint Commission on Accreditation of Healthcare Organizations (Joint Commission) still struggle with using unapproved abbreviations, says a field surveyor with the Joint Commission. -
‘Pearls’ of wisdom about NAC administration
A certain soft drink has led the way in tests for masking the taste and smell of oral N-acetylcysteine (NAC) in treating acetaminophen poisoning, according to a pharmacist who directs a poison control center. To ensure the best tolerance, however, use the intravenous (IV) formulation rather than the oral one. -
News Briefs
Preferred treatment for advanced ovarian cancer announced; CDC updates child/adolescent immunization schedule; CDC: Millions of people carry drug-resistant bacteria; Study: Many patients with NSTE ACS given wrong dose; FDA: Post-marketing rosiglitazone maleate (Avandia) warning -
New FDA Approvals: New treatment approved for advanced kidney cancer
The first treatment for advanced renal cell carcinoma has been approved by the FDA in more than a decade. -
Drug Criteria & Outcomes: Paricalcitol (Zemplar) Formulary Evaluation
Strengths/dosage forms available: Paricalcitol is available in 1 mL and 2 mL single-dose vials (5 mcg/mL) of aqueous solution for intravenous (IV) injection, as well as in 1 mcg, 2 mcg, and 4 mcg capsules.